Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users

Healthy Clinical Trial

Official title:

A Randomized, Double-Blind, Active- and Placebo-Controlled, Single-Dummy, 4-Way Crossover Study to Determine the Abuse Potential of Pitolisant Compared to Phentermine and Placebo, in Healthy, Non-Dependent Recreational Stimulant Users

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03152123
• Other study ID #: P16-02 / BF2.649
• Status: Completed
• Phase: Phase 1
• First received: May 10, 2017
• Last updated: November 9, 2017
• Start date: March 15, 2017
• Est. completion date: October 23, 2017

Study information

• Verified date: November 2017
• Source: Bioprojet
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the abuse potential of single doses of pitolisant relative to phentermine HCl and placebo, when administered to healthy, non-dependent, recreational stimulant users.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: October 23, 2017
• Est. primary completion date: October 23, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy male or female subjects 18 to 55 years of age, inclusive.

• Must understand and provide written informed consent, prior to the initiation of any protocol-specific procedures.

• Current stimulant users who have used stimulants for recreational (non-therapeutic) purposes, (ie, for psychoactive effects) at least 10 times in the past year and used stimulants at least 1 time in the 8 weeks before Screening.

• Female subjects of childbearing potential with male sexual partners must be using and willing to continue using medically acceptable contraception for at least 1 month prior to Screening (at least 3 months for oral and transdermal contraceptives) and for at least 1 month after last study drug administration.

• Male subjects with female sexual partners of childbearing potential must be using and willing to continue using medically acceptable contraception from Screening and for at least 1 month after the last study drug administration.

• Able to speak, read, and understand English sufficiently to allow completion of all study assessments.

Exclusion Criteria:

• Substance or alcohol dependence (excluding nicotine and caffeine) within the past 2 years, as defined by the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition - Text Revision (DSM IV-TR), and/or has ever participated or plans to participate in a substance or alcohol rehabilitation program to treat their substance or alcohol dependence.

• History or presence of clinically significant abnormality as assessed by physical examination, medical history, vital signs, or laboratory values, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results.

• History or presence of motor tics, Tourette's syndrome, or significant anxiety, tension, or agitation.

• Presence of thyrotoxicosis, advanced arteriosclerosis, glaucoma, pheochromocytoma, acid related gastric disorders, or peripheral vasculopathy (including Raynaud's phenomenon).

• History or presence of cardiovascular disorder (eg, moderate to severe hypertension, angina, arterial occlusive disease, heart failure, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies [disorders caused by the dysfunction of ion channels]), or other serious cardia problems.

• History or presence of CNS abnormalities (eg, cerebral aneurysm, vascular abnormalities, stroke), seizures, convulsions, or epilepsy.

• History or presence of clinically significant abnormality as assessed by ECG, long QTc syndrome (eg, syncope or arrhythmia), or presence QTcF interval >450 msec.

• Evidence of clinically significant hepatic or renal impairment including alanine aminotransferase or aspartate aminotransferase > 1.5 × the upper limit of normal (ULN) or bilirubin > 1 × ULN.

• Positive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

• History of allergy or hypersensitivity to pitolisant, phentermine HCl, or related drugs (eg, sympathomimetic amines) or known excipients of any of the drug products in this study (eg, lactose).

• History of severe allergic reaction (including anaphylaxis) to any substance or previous status asthmaticus.

• Subjects with any history of suicidal ideation or suicidal behavior, as assessed by the C SSRS (baseline version).

• Treatment with an investigational drug within 5 times the elimination half-life, if known (eg, a marketed product), or within 30 days (if the elimination half-life is unknown) prior to the first study drug administration or is concurrently enrolled in any research, judged not to be scientifically or medically compatible with this study.

Related Conditions & MeSH terms

• Drug Abuse
• Healthy
• Substance-Related Disorders

Intervention

Drug:
• Pitolisant
Pitolisant 40 mg or 240 mg (tablets over-capsuled)
• Placebos
tablets over-capsuled
• Phentermine
Phentermine 60 mg (capsule over-capsuled)

Locations

Country	Name	City	State
Canada	INC Research	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Bioprojet

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum effect (Emax) on Drug Liking visual analog scale (VAS)	Drug liking VAS is one of the measures of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm).	Within 24 hours post-dose
Secondary	Drug Liking VAS (minimum effect [Emin] and time-averaged area under the effect curve to 24 hours after study drug administration [TA_AUE])	Drug liking VAS is one of the measures of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm).	Within 24 hours post-dose
Secondary	Overall Drug Liking VAS (Emax/Emin)	Overall drug liking VAS is one of the measures of balance of effects that assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carryover effects). A 100 mm bipolar VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = "strong disliking", 50 mm= "neither like nor dislike", and 100 mm= "strong liking").	Within 24 hours post-dose
Secondary	Take Drug Again VAS (Emax)	Take drug again VAS is one of the measures of balance of effects. It is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm bipolar VAS with score ranging from 0 mm to 100 mm (score of 0 mm = "definitely not", 50 mm = "do not care", and 100 mm = "definitely so").	Within 24 hours post-dose
Secondary	Good Effects VAS (Emax and TA_AUE)	Good drug effects VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).	Within 24 hours post-dose
Secondary	Bad Effects VAS (Emax and TA_AUE)	Bad effects VAS is one of the measures of negative effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).	Within 24 hours post-dose
Secondary	ARCI-A scale (Emax and TA_AUE)	ARCI-A is measure of other stimulant effects. It is a set of 13 questions in which each question contributes to total score. Participants select 'False' / 'True' for response. One point given for each response that agrees with scoring direction, true items receive score of 1 if answer 'True', false items receive score of 1 if answer 'False'. No points if answer is opposite to scoring direction. Score range: 0 to 13, higher score indicated higher other subjective effects.	Within 24 hours post-dose
Secondary	ARCI-BG scale (Emax and TA_AUE)	ARCI-BG is measure of other subjective effects. It is a set of 13 questions in which each question contributes to total score. Participants select 'False' / 'True' for response. One point given for each response that agrees with scoring direction, true items receive score of 1 if answer 'True', false items receive score of 1 if answer 'False'. No points if answer is opposite to scoring direction. Score range: 0 to 13, higher score indicated higher other subjective effects.	Within 24 hours post-dose
Secondary	Agitation/Relaxation VAS (Emax and TA_AUE)	Agitation/Relaxation VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).	Within 24 hours post-dose
Secondary	Drug Similarity VAS (score at 24 hours after study drug administration)	Drug similarity VAS is one of the measures of other subjective effects. It assesses the similarity of the drug recently received by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= not at all similar) to 'extremely' (score of 100 mm= very similar).	Within 24 hours post-dose
Secondary	Safety and tolerability of Pitolisan HCl as assessed by AEs	AEs assessment	Up to 6 weeks
Secondary	Safety and tolerability of Pitolisan HCl by laboratory assessments	Laboratory assessments	Up to 6 weeks
Secondary	Safety and tolerability of Pitolisan HCl as assessed by 12-lead ECGs	12-lead ECGs assessments	Up to 6 weeks
Secondary	Safety and tolerability of Pitolisan HCl as assessed by vital signs	Vital signs assessment	Up to 6 weeks
Secondary	Safety and tolerability of Pitolisan HCl as assessed by physical examination	Physical examination assessment	Up to 6 weeks